Navigation Links
Study Demonstrates Percutaneous Tibial Nerve Stimulation Offers More Cost-Effective OAB Treatment Than Sacral Nerve Stimulation
Date:12/6/2012

www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140

 

EVC Group

Doug Sherk/Jenifer Kirtland

(Investors), 415.896.6820

Chris Gale (Media), 646.201.5431

 


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)...  PowerVision, Inc., a medical device company developing ... announced that Douglas D. Koch , M.D., ... and Professor of Ophthalmology, at Baylor College of ... As a recipient of several ... Lifetime Achievement award, Koch will join the distinguished ...
(Date:7/21/2014)... July 21, 2014  AVT, Inc. (OTC Markets: ... retailing, micro-stores, custom vending machines and kiosks, commented ... medicine dispensing systems, which can be used by ... marijuana dispensaries. AVT,s newly designed systems provide for ... and regulated products. "We are getting ...
(Date:7/21/2014)... July 21, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... and Drug Administration (FDA) accepted the company,s Investigational New ... the safety and efficacy of AVP-786, Avanir,s next generation ... AVP-786 for the adjunctive treatment of major depressive disorder ... "The endorsement of this Phase II study ...
Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4Technology Driving Cannabis Industry 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5
(Date:7/22/2014)... Two recent studies indicate that previously untreated ... more abused as children than those without these disorders. And ... ADHD children reduces their otherwise higher risk of later ... causation. , Since over 25% of the population suffer from ... and best treatment for these disorders so as to prevent ...
(Date:7/22/2014)... A new and technologically unique procedure ... results that are surprising even the most skeptical plastic ... with radio frequency, ThermiTight has been dubbed “InjectableRF” because ... skin to “inject” heat to the tissues which cause ... treatment solution for skin laxity produces results in weeks, ...
(Date:7/21/2014)... cancer cells could boost the effectiveness of chemotherapy to ... new study reports. , Scientists at The Institute of ... engineered version of the virus used to vaccinate against ... isolated limb perfusion chemotherapy given directly to blood ... alternative to amputation was more effective in rats ...
(Date:7/21/2014)... 22, 2014 Recently, Stwd.co.uk, a popular supplier ... wedding dresses. Additionally, the company’s chief executive officer has stated ... prices, up to 58% off. , “All our new and ... offer is launched to bring huge benefits to worldwide customers. ... cheap wedding outfits. By the way, we offer custom made ...
(Date:7/21/2014)... As reported by CBS Local Pittsburgh ... Raise Addiction Awareness (7/15), thrill-seeking participants raised $100,000 to ... building in Downtown Philly. 100 people, including some well-known ... Westin Convention Center Hotel. Some of the participants shared ... participated because his son killed himself after a long ...
Breaking Medicine News(10 mins):Health News:New Studies Reporting a Higher Incidence of Child Abuse in ADHD and Dyslexia Suggest a Need for Early Medical Treatment, Notes Dr. Harold Levinson 2Health News:New Studies Reporting a Higher Incidence of Child Abuse in ADHD and Dyslexia Suggest a Need for Early Medical Treatment, Notes Dr. Harold Levinson 3Health News:New Studies Reporting a Higher Incidence of Child Abuse in ADHD and Dyslexia Suggest a Need for Early Medical Treatment, Notes Dr. Harold Levinson 4Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:2014 Cheap Wedding Dresses, Newest Items Offered by Professional Company Stwd.co.uk 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3
... for patients in just the first six months after they ... in Canada, according to a study presented today at the ... Ischemic Stroke (BURST) study found that the direct and indirect ... in the six-month period following a new stroke. There are ...
... June 8, 2010The new Center for Medicare and Medicaid ... and implementing payment initiatives, continuously monitor their impact, and ... in order to realize the potential for improved health ... Health Affairs article by Commonwealth Fund researchers. ...
... (June 7, 2010) Researchers from the BC Centre ... British Columbia today released a comprehensive study revealing that ... would create significant benefits for individuals infected with HIV ... modeling study, published in the research journal PLoS ...
... at Purdue University have developed a potential new tool ... and crime-scene forensics. The technique uses a combination ... tiny particles, such as bacteria, viruses and DNA, which ... either light or electric fields separately are able to ...
... target cancerous plasma cells appears promising in treating multiple myeloma, ... at the drug elotuzumab, an antibody which is designed to ... cells. The antibody has the potential to attach to malignant ... early stage trial combined elotuzumab with bortezomib, or Velcade, one ...
... common in younger men, and it,s often more aggressive in ... of Michigan Comprehensive Cancer Center has found that a series ... cancer. Researchers believe that genetics and traditional screening methods ... cancer in younger men. "This is a potential ...
Cached Medicine News:Health News:Cost of caring for stroke patients double that of earlier estimates 2Health News:Cost of caring for stroke patients double that of earlier estimates 3Health News:Center for Medicare and Medicaid Innovation must implement payment reforms rapidly 2Health News:Center for Medicare and Medicaid Innovation must implement payment reforms rapidly 3Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 3Health News:New method manipulates particles for sensors, crime scene testing 2Health News:New method manipulates particles for sensors, crime scene testing 3
... base with vacuum stage, porous vacuum plate, reservoir ... instructions. The Model 785 vacuum blotter quickly ... agarose gel onto a nylon membrane. Because it ... nucleic acid samples can be separated on a ...
... regulator. The Model 785 vacuum blotter ... from an agarose gel onto a nylon ... min for transfer, the nucleic acid samples ... to a membrane, and the hybridization reaction ...
Inquire...
... proven electrophoretic transfer apparatus incorporating state-of-the-art plate electrodes ... allows for a very close positioning of the ... power source such as a battery charger, creates ... exceptionally rapid and exact electrophoretic transfer. ...
Medicine Products: